The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 21, 2021

Filed:

Jun. 21, 2018
Applicants:

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Centre Leon Berard, Lyons, FR;

Inventors:

Patrick Mehlen, Serezin du Rhone, FR;

Agnes Bernet, Genas, FR;

Julien Fitamant, Lyons, FR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C12Q 1/18 (2006.01); C07K 16/22 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); C07K 16/22 (2013.01); C12Q 1/18 (2013.01); G01N 33/574 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); G01N 2333/475 (2013.01); G01N 2500/02 (2013.01); G01N 2800/52 (2013.01);
Abstract

The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.


Find Patent Forward Citations

Loading…